At the ESMO Congress 2024, Andrea Necchi, MD, of San Raffaele Hospital and Scientific Institute, and Karine Tawagi, MD, of University of Illinois, highlight some the challenges that currently exist in the treatment of penile cancer, including “suboptimal” therapy options in the neoadjuvant and adjuvant space and a need for better biomarkers. Dr. Necchi also opines on the trials that have him excited about the future of treatment in this rare disease, such as HERCULES. ...
Testicular, Penile, and Rare Malignancies
Advertisement
Latest News
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Advertisement
Latest News
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.